Almonertinib vs Icotinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Almonertinib

Marketed by Hansoh Pharmaceutical Group and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04500717 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT04841811 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From baseline, then every 6 weeks, until disease progression or discontinuation from study. From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.): ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). (met)

Result source: NCT04500717

Icotinib

Marketed by Betta Pharmaceuticals Co.

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01040780 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.

Next expected readout: October 2030 · NCT07458919 (registry estimate)

Reported efficacy

Progression Free Survival (12 months): Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006 (met)

Result source: NCT01719536

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlmonertinibIcotinib
PFS, median—Trial running · NCT064170084.6 vs 3.4vs Gefitinibn 199NCT01040780
1 other result
OS, median—Trial running · NCT0641700813.3 vs 13.9vs Gefitinibn 199NCT01040780
ORR—Trial running · NCT06417008—Not posted · NCT04206072
Duration of response, median—Trial running · NCT06417008—Not posted · NCT04206072

PFS, median

Almonertinib
—Trial running · NCT06417008
Icotinib
4.6 vs 3.4vs Gefitinibn 199NCT01040780
1 other result

OS, median

Almonertinib
—Trial running · NCT06417008
Icotinib
13.3 vs 13.9vs Gefitinibn 199NCT01040780

ORR

Almonertinib
—Trial running · NCT06417008
Icotinib
—Not posted · NCT04206072

Duration of response, median

Almonertinib
—Trial running · NCT06417008
Icotinib
—Not posted · NCT04206072
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Almonertinib
ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205). NCT04500717 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Almonertinib: 0 of 4 rows · Icotinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIcotinib
Dropout rate
0.5%a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
0%
NCT02264210 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
—
NCT02264210 · Phase 2 · registry result, not featured evidence
Serious AEs
6.5%a
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
6.3%
NCT02264210 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
rash 40.5%
diarrhea 21.5%
pain 18%
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
rash 39.7% (placebo 0%)
diarrhoea 20.6% (placebo 0%)
pain 11.1% (placebo 0%)
NCT02264210 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Icotinib

PFS 4.6 vs 3.4 Gefitinib months
time to event · months
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
11.2 vs 7.9 cisplatin/pemetrexed+pemetrexed maintenance months
NCT01719536 · Phase 3 · sponsor-reported, not registry data
Overall Survival 13.3 vs 13.9 Gefitinib months
time to event · months
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Stable Disease 47.7% (n=199) vs 47.7% (n=196) Gefitinib
absolute value · percentage points
Stable Disease (SD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Progressive Disease 21.1% (n=199) vs 20.5% (n=196) Gefitinib
absolute value · percentage points
Progressive Disease (PD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease Control 75.4% (n=199) vs 74.9% (n=196) Gefitinib
absolute value · percentage points
Disease Control (CR+PR+SD)
NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Disease-Free Survival 96.1 vs 84 placebo % of time @ 156wk
absolute value · % of time
NCT02264210 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almonertinib's landscape · Icotinib's landscape